RS-2024-00338363

A Study on the Development of USP1 inhibitor candidate as a New Synthetic Lethality Target for the Treatment of BRCA (-) and HRD (+) Cancer

AIGEN Sciences

Disease Area	***Oncology***
Product Type	Small molecule
Indication	BRCA (-) cancers, HRD (+) cancers, CCNE-1 (+) cancers
Target	USP1
Mechanism of Action	Synthetic lethality by the ubiquitination of PCNA
Competitiveness	KSQ4279: phase 1 ISM-3091: phase 1
Development Stage	***Lead optimization (Lead to candidate)***
Route of Administration	oral

Key Data

AIG07016: lead compound

- Good selectivity for DUB panel
- Good selectivity for BRCA wild type cancer cell
- Synergism with PARP inhibitor

Selectivity for DUB panel



Cell growth inhibition: BRCA1 mt vs. wt



Combination with Olaparib



IP

Filed